

January 10, 2018

**Financial Industry Regulatory Authority (FINRA)
New York Stock Exchange (NYSE)**

Syngenta International AG

DR CUSIP: 87160A100

DR ISIN: US87160A1007

DR Ticker Symbol: SYT

Ratio (DR: Underlying Shares): 5:1

Syngenta International AG (“Syngenta”) was acquired by CNAC Saturn (NL) B.V. in exchange for cash effective January 10, 2018. Under the terms of the compulsory acquisition each Syngenta ordinary share was exchanged for USD 465. BNY Mellon as Depositary will distribute the net cash proceeds received to holders of Depositary Receipts (“DRs”) representing Syngenta ordinary shares.

DR holders of Syngenta are now entitled to receive the net cash proceeds on a pro-rata basis.

Effective January 16, 2018 Syngenta DR holders will be required on a mandatory basis to surrender their DRs to BNY Mellon for cancellation and exchange for the cash proceeds as follows:

Gross Rate per Depositary Share (“DS”):	\$93.000000
Cancellation fee per DS:	<u>(\$ 0.050000)</u>
Net Rate per DS:	\$92.950000

Please be advised the Syngenta Deposit Agreement will terminate on the earlier of the 90th day after the date of this notice and the day on which there are no remaining outstanding ADSs.

Thank you in advance for your assistance. Feel free to contact me should you require further assistance.

Sincerely,

Richie Bab Boyboy

T: +212-815-3158 / F: + 212-571-3050

GCATINFO@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt (“DR”) holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.